These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 34864894)

  • 1. Definition of low disease activity state based on the SLE-DAS: derivation and validation in a multicentre real-life cohort.
    Assunção H; Jesus D; Larosa M; Henriques C; Matos A; Le Guern V; Rubiño F; da Silva JAP; Rua-Figueroa I; Costedoat-Chalumeau N; Doria A; Inês LS
    Rheumatology (Oxford); 2022 Aug; 61(8):3309-3316. PubMed ID: 34864894
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Validity of systemic lupus erythematosus disease activity score (SLE-DAS) for definition of lupus low disease activity state (LLDAS).
    Abdelhady EI; Rabie M; Hassan RA
    Clin Rheumatol; 2021 Nov; 40(11):4553-4558. PubMed ID: 34142298
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Systemic Lupus Erythematosus Disease Activity Score (SLE-DAS) enables accurate and user-friendly definitions of clinical remission and categories of disease activity.
    Jesus D; Larosa M; Henriques C; Matos A; Zen M; Tomé P; Alves V; Costa N; Le Guern V; Iaccarino L; Costedoat-Chalumeau N; Doria A; Inês LS
    Ann Rheum Dis; 2021 Dec; 80(12):1568-1574. PubMed ID: 34407927
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Derivation and validation of the SLE Disease Activity Score (SLE-DAS): a new SLE continuous measure with high sensitivity for changes in disease activity.
    Jesus D; Matos A; Henriques C; Zen M; Larosa M; Iaccarino L; Da Silva JAP; Doria A; Inês LS
    Ann Rheum Dis; 2019 Mar; 78(3):365-371. PubMed ID: 30626657
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Does expert opinion match the definition of lupus low disease activity state? Prospective analysis of 500 patients from a Spanish multicentre cohort.
    Altabás-González I; Rúa-Figueroa I; Rubiño F; Mouriño Rodríguez C; Hernández-Rodríguez I; Menor Almagro R; Uriarte Isacelaya E; Tomero Muriel E; Salman-Monte TC; Carrión-Barberà I; Galindo M; Rodríguez Almaraz EM; Jiménez N; Inês L; Pego-Reigosa JM
    Rheumatology (Oxford); 2023 Mar; 62(3):1162-1169. PubMed ID: 35961050
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Systemic Lupus Erythematosus Disease Activity Score Remission and Low Disease Activity States Discriminate Drug From Placebo and Better Health-Related Quality of Life.
    Jesus D; Henriques C; Matos A; Doria A; Inês LS
    Arthritis Care Res (Hoboken); 2024 Jun; 76(6):788-795. PubMed ID: 38258369
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predictors of flare in SLE patients fulfilling lupus low disease activity state: a cohort study of 292 patients with 36-month follow-up.
    Cunha RN; Saraiva L; Jesus D; Doria A; da Silva JP; Inês LS
    Rheumatology (Oxford); 2023 Nov; 62(11):3627-3635. PubMed ID: 36847423
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Attainment of low disease activity and remission targets reduces the risk of severe flare and new damage in childhood lupus.
    Smith EMD; Tharmaratnam K; Al-Abadi E; Armon K; Bailey K; Brennan M; Ciurtin C; Gardner-Medwin J; Haslam KE; Hawley D; Leahy A; Leone V; Malik G; McLaren Z; Pilkington C; Ramanan AV; Rangaraj S; Ratcliffe A; Riley P; Sen E; Sridhar A; Wilkinson N; Hedrich CM; Jorgensen A; Beresford MW
    Rheumatology (Oxford); 2022 Aug; 61(8):3378-3389. PubMed ID: 34894234
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular characterisation of lupus low disease activity state (LLDAS) and DORIS remission by whole-blood transcriptome-based pathways in a pan-European systemic lupus erythematosus cohort.
    Parodis I; Lindblom J; Barturen G; Ortega-Castro R; Cervera R; Pers JO; Genre F; Hiepe F; Gerosa M; Kovács L; De Langhe E; Piantoni S; Stummvoll G; Vasconcelos C; Vigone B; Witte T; ; Alarcón-Riquelme ME; Beretta L
    Ann Rheum Dis; 2024 Jun; 83(7):889-900. PubMed ID: 38373843
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Application of SLE-DAS to assess subcutaneous belimumab efficacy in a cohort of systemic lupus erythematosus patients.
    Ceccarelli F; Picciariello L; Natalucci F; Moretti V; Spinelli FR; Alessandri C; Conti F
    Clin Exp Rheumatol; 2024 Jul; 42(7):1491-1494. PubMed ID: 38819948
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Does expert opinion match the operational definition of the Lupus Low Disease Activity State (LLDAS)? A case-based construct validity study.
    Golder V; Huq M; Franklyn K; Calderone A; Lateef A; Lau CS; Lee ALH; Navarra STV; Godfrey T; Oon S; Hoi AYB; Morand EF; Nikpour M
    Semin Arthritis Rheum; 2017 Jun; 46(6):798-803. PubMed ID: 28216192
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Definition and initial validation of a Lupus Low Disease Activity State (LLDAS).
    Franklyn K; Lau CS; Navarra SV; Louthrenoo W; Lateef A; Hamijoyo L; Wahono CS; Chen SL; Jin O; Morton S; Hoi A; Huq M; Nikpour M; Morand EF;
    Ann Rheum Dis; 2016 Sep; 75(9):1615-21. PubMed ID: 26458737
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Frequencies and predictors of the Lupus Low Disease Activity State and remission in treatment-naïve patients with systemic lupus erythematosus.
    Gao D; Hao Y; Mu L; Xie W; Fan Y; Ji L; Zhang Z
    Rheumatology (Oxford); 2020 Nov; 59(11):3400-3407. PubMed ID: 32337549
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Remission and low disease activity in Polish patients with systemic lupus erythematosus - real-life, five-year follow-up outcomes.
    Pawlak-Buś K; Schmidt W; Leszczyński P
    Eur Rev Med Pharmacol Sci; 2023 Feb; 27(3):949-959. PubMed ID: 36808341
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The SLE-DAS provides an accurate and feasible flare tool in the clinical setting: a validation study.
    Saraiva L; Cunha RN; Jesus D; Gatto M; Zen M; Iaccarino L; da Silva JAP; Doria A; Inês LS
    Rheumatology (Oxford); 2024 Apr; 63(4):1123-1129. PubMed ID: 37458482
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Caveats and pitfalls in defining low disease activity in systemic lupus erythematosus.
    Samões B; Zen M; Abelha-Aleixo J; Gatto M; Doria A
    Autoimmun Rev; 2022 Oct; 21(10):103165. PubMed ID: 35931316
    [TBL] [Abstract][Full Text] [Related]  

  • 17. LLDAS is an attainable treat-to-target goal in childhood-onset SLE.
    Wahadat MJ; van den Berg L; Timmermans D; van Rijswijk K; van Dijk-Hummelman A; Bakx S; Verkaaik M; Versnel MA; Kamphuis S
    Lupus Sci Med; 2021 Dec; 8(1):. PubMed ID: 34969874
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lupus Low Disease Activity State (LLDAS) attainment discriminates responders in a systemic lupus erythematosus trial:
    Morand EF; Trasieva T; Berglind A; Illei GG; Tummala R
    Ann Rheum Dis; 2018 May; 77(5):706-713. PubMed ID: 29420200
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Performance of SLE responder index and lupus low disease activity state in real life: A prospective cohort study.
    Ramirez GA; Canti V; Moiola L; Magnoni M; Rovere-Querini P; Coletto LA; Dagna L; Manfredi AA; Bozzolo EP
    Int J Rheum Dis; 2019 Sep; 22(9):1752-1761. PubMed ID: 31379114
    [TBL] [Abstract][Full Text] [Related]  

  • 20. How can we define low disease activity in systemic lupus erythematosus?
    Tselios K; Gladman DD; Urowitz MB
    Semin Arthritis Rheum; 2019 Jun; 48(6):1035-1040. PubMed ID: 30415943
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.